J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients

Johnson & Johnson announced positive Phase 1b trial results for its dual-targeting CAR-T therapy (JNJ-4496) in relapsed or refractory large B-cell lymphoma, demonstrating a 100% objective response rate in patients with one prior treatment and 92% in those with two or more. The trial, which is assessing the safety and efficacy of the therapy that targets both CD19 and CD20, showed manageable safety profiles with no grade 3 or 4 cytokine release syndrome, marking a potential advancement over existing single-antigen CAR-T therapies and signaling J&J's renewed commitment to the CAR-T space following its 2023 collaboration with AbelZeta.

Analysis

Johnson & Johnson has reported encouraging initial efficacy and manageable safety data from its Phase 1b trial of JNJ-4496, a dual-targeting (CD19 and CD20) CAR-T therapy for relapsed or refractory large B-cell lymphoma. In patients receiving the recommended Phase 2 dose of 75 million CAR T-cells, the objective response rate (ORR) was 100% for 10 patients with one prior line of treatment (8 complete responses) and 92% for 12 patients with two or more prior therapies (75% complete response rate), observed at a median follow-up of 4 months. This dual-antigen approach is notable given that existing single-antigen CD19 CAR-T therapies yield long-term remissions in only about 40% of patients. On the safety front, while 84% of 25 patients experienced grade 3 or 4 treatment-related adverse events and 28% had serious side effects, there were no instances of grade 3 or 4 cytokine release syndrome, a significant concern with CAR-T therapies; one patient experienced grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS), and another with CNS lymphoma had grade 3 ICANS. The company did not specify dose-limiting toxicities in its announcement. This development, stemming from a $245 million upfront payment in a 2023 deal with AbelZeta for ex-China rights, signals J&J's strategic re-engagement in the CAR-T field, contrasting sharply with recent struggles and shutdowns among smaller cell therapy biotechs like Carisma Therapeutics, Vor Bio, and Cargo Therapeutics, suggesting J&J's scale may enable it to navigate the sector's high costs and clinical complexities more effectively.

Key Decisions for Investors

• Investors should interpret these early JNJ-4496 results as a significant positive catalyst for Johnson & Johnson's oncology pipeline, warranting close observation of upcoming data from the ongoing global Phase 1b study and subsequent trials, particularly focusing on long-term durability and the evolving safety profile.
• The promising efficacy of the dual-targeting CAR-T therapy, especially the high complete response rates and absence of severe cytokine release syndrome, positions Johnson & Johnson to potentially enhance treatment paradigms for large B-cell lymphoma and strengthen its competitive footing against established CAR-T players.
• Despite the encouraging initial data, the reported 84% rate of grade 3/4 treatment-related adverse events necessitates continued scrutiny of the therapy's overall benefit-risk profile as more comprehensive and mature data becomes available, and investors should remain mindful of the inherent clinical and commercialization risks associated with CAR-T development.